ArticleHemaSphere2023

Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab.

Cyrielle Rodier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.